BiomX Inc. CEO, Jonathan Solomon, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8th in New York City. The presentation will focus on positive results from the Phase 2 trial of BX211, a phage treatment for Diabetic Foot Infections (DFO) caused by S. aureus bacteria. The trial showed a statistically significant reduction in ulcer size, depth, and expansion of ulcer area. BiomX plans a registrational trial pending FDA feedback. BiomX is a clinical-stage company developing phage therapies for chronic diseases. Investors can request meetings through H.C. Wainwright.

Read more at GlobeNewswire: BiomX CEO to Present at H.C. Wainwright 27th Annual Global